We analyzed the spectrum of thyroid nodules in patients attending the endocrinology unit care of the Kinshasa University Hospital and assessed their associated factors. We conducted a cross-sectional study, performing descriptive statistics and logistic regression. From the 888 enrolled patients, thyroid nodules were detected in 658 patients (74.1%), as mononodules in 22.5% and multiple nodules in 77.5%. Thyroid function was normal in 71.3% cases, while hyperthyroidism and hypothyroidism were found in 26.1% and 2.6% of cases, respectively. Women were more affected than men (75.1% vs. 63.6%; p = 0.03). Patients with thyroid nodules were older (44 ± 12 vs. 38 ± 12 years; p < 0.001), with a family history of goiter (38.3% vs. 27.4%; p = 0.003) and residence in the iodine-deficient region (51.7% vs. 38.8%; p = 0.012); they had a higher proportion of longer delays to consultation (47% vs. 20%; p < 0.001), but a higher rate of normal thyroid function (85.5% vs. 3 1.3%; p < 0.001). Thyroid nodules were associated with the delay to consultation (for duration ≥ three years, OR: 6.560 [95% CI: 3.525–12.208)], multiparity (present vs. absent: 2.863 [1.475–5.557]) and family history of goiter (present vs. absent: 2.086 [95% CI:1.231–3.534]) in female patients alone. The high frequency of thyroid nodules observed requires measures aimed at early detection in the population, the training of doctors involved in the management and the strengthening of technical platforms in our hospitals.
Background: Primary malignant melanomas of the Gastric mucosa are uncommon. Most cases of Gastrointestinal (GI) melanomas are secondary, arising from metastasis at distant sites. GI melanomas have been associated with dismal prognosis, owing to their identification at more advanced stages. The purpose of this study is to investigate the clinical characteristics, survival outcomes, and prognostic factors of patients with primary GI melanoma in the past decade. Methods: A total of 399 patients diagnosed with Primary GI melanoma, between 2008 and 2017, were ultimately enrolled in our study by retrieving the Surveillance, Epidemiology, and End Results (SEER) database. We analyzed demographics, clinical characteristics, and overall mortality (OM) as well as cancer-specific mortality (CSM) of primary GI melanoma. Variables with a p value < 0.1 in the univariate Cox regression were incorporated into the multivariate Cox model to determine the independent prognostic factors, with a hazard ratio (HR) of greater than 1 representing adverse prognostic factors.Results: From a sample of 399 primary GI melanomas, male gender (56.4%), age range 60-79 years (52.88%), non-Hispanic whites (70.18%), as well as annual income of $75,000+ yearly (30.33%) were the most represented. Crude analysis revealed higher overall mortality (OM) in age group 80+ (HR = 4.042, 95% CI 1.732 - 9.433, p = 0.001), stomach location of the tumor (HR = 3.261, 95% CI 1.658 - 6.417, p = 0.001), distant metastases (HR = 2.967, 95% CI 2.22 - 3.965, p=0 ), Nonmetropolitan counties not adjacent to a metropolitan area ( HR= 2.211, 95 % CI 1.253-3.9, p=0.006 ), and chemotherapy ( HR= 1.417, 95% CI 1.078-1.863, p=0.012). Crude analysis for Cancer specific mortality (CSM) also revealed higher mortality in the same groups. Multivariate cox proportional hazard regression analyses only revealed higher OM in age group 80+ (HR = 5.653, 95% CI 2.212 - 14.445, p=0), stomach location of the tumor (HR = 2.821, 95% CI 1.265 - 6.292, p = 0.011), and distant metastases (HR= 4.491, 95% CI 3.115-6.476, p=0). Multivariate cox proportional hazard regression analyses of CSM also revealed higher mortality of the same groups.Conclusion: Primary GI melanoma is a rare entity. Only a few studies have been carried out in recent years to evaluate factors affecting the survival and mortality of primary GI melanoma. The paucity of data on primary GI melanoma governed the need of this study. In this population-based retrospective cohort study using the SEER database, we found that age at diagnosis, the primary site of the disease, and advanced disease at diagnosis were independent factors predicting poor prognosis. Furthermore, even surgical resection did not significantly impact the overall mortality or the cancer-specific mortality. This cohort paves the path for further prospective studies identifying individuals at an increased risk of primary GI melanomas, earlier and closer screenings in such individuals, and then evaluation of long-term prognosis in these patients as age and advanced disease were both independent risk factors predicting poor prognosis in our study.
1. Background: Primary malignant melanomas of the Gastric mucosa are uncommon. Most cases of Gastrointestinal (GI) melanomas are secondary, arising from metastasis at distant sites. GI melanomas have been associated with dismal prognosis, owing to their identification at more advanced stages. The purpose of this study is to investigate the clinical characteristics, survival outcomes, and prognostic factors of patients with primary GI melanoma in the past decade. 2. Methods: A total of 399 patients diagnosed with Primary GI melanoma, between 2008 and 2017, were ultimately enrolled in our study by retrieving the Surveillance, Epidemiology, and End Results (SEER) database. We analyzed demographics, clinical characteristics, and overall mortality (OM) as well as cancer-specific mortality (CSM) of primary GI melanoma. Variables with a p value < 0.1 in the univariate Cox regression were incorporated into the multivariate Cox model to determine the independent prognostic factors, with a hazard ratio (HR) of greater than 1 representing adverse prognostic factors. 3. Results: From a sample of 399 primary GI melanomas, male gender (56.4%), age range 60-79 years (52.88%), non-Hispanic whites (70.18%), as well as annual income of $75,000+ yearly (30.33%) were the most represented. Crude analysis revealed higher overall mortality (OM) in age group 80+ (HR = 4.042, 95% CI 1.732 - 9.433, p = 0.001), stomach location of the tumor (HR = 3.261, 95% CI 1.658 - 6.417, p = 0.001), distant metastases (HR = 2.967, 95% CI 2.22 - 3.965, p=0 ), Nonmetropolitan counties not adjacent to a metropolitan area ( HR= 2.211, 95 % CI 1.253-3.9, p=0.006 ), and chemotherapy ( HR= 1.417, 95% CI 1.078-1.863, p=0.012). Crude analysis for Cancer specific mortality (CSM) also revealed higher mortality in the same groups. Multivariate cox proportional hazard regression analyses only revealed higher OM in age group 80+ (HR = 5.653, 95% CI 2.212 - 14.445, p=0), stomach location of the tumor (HR = 2.821, 95% CI 1.265 - 6.292, p = 0.011), and distant metastases (HR= 4.491, 95% CI 3.115-6.476, p=0). Multivariate cox proportional hazard regression analyses of CSM also revealed higher mortality of the same groups.4. Conclusion: Primary GI melanoma is a rare entity. Only a few studies have been carried out in recent years to evaluate factors affecting the survival and mortality of primary GI melanoma. The paucity of data on primary GI melanoma governed the need of this study. In this population-based retrospective cohort study using the SEER database, we found that age at diagnosis, the primary site of the disease, and advanced disease at diagnosis were independent factors predicting poor prognosis. Furthermore, even surgical resection did not significantly impact the overall mortality or the cancer-specific mortality. This cohort paves the path for further prospective studies identifying individuals at an increased risk of primary GI melanomas, earlier and closer screenings in such individuals, and then evaluation of long-term prognosis in these patients as age and advanced disease were both independent risk factors predicting poor prognosis in our study.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.